Full-Time

Director Advertising and Promotional Compliance

Posted on 7/8/2026

Deadline 8/8/26
AstraZeneca

AstraZeneca

10,001+ employees

Global pharmaceutical company developing prescription medicines

Compensation Overview

$193.3k - $289.9k/yr

+ Short-term incentive bonuses + Equity-based awards + Commissions

Boston, MA, USA

Hybrid

Three days per week in the office required.

Bachelor's, Master's, PharmD, JD

Category
Legal & Compliance (1)
Required Skills
FDA Regulations

Get referred to AstraZeneca

See people who can refer or advise you

Requirements
  • Bachelor’s degree
  • 7+ years pharmaceutical industry in regulatory affairs and/or advertising and promotion
  • Expertise in US advertising and promotional regulations and the current regulatory environment
  • Experience communicating and negotiating directly with OPDP and/or APLB
  • Experience leading a team or experience having direct reports
  • Experience with global standards for advertising and promotional compliance
  • Excellent written and verbal skills and strong interpersonal skills
  • Consistent track record practicing sound judgment as it relates to risk assessment
  • Knowledgeable on industry compliance requirements and non-compliance examples and trends
  • Demonstrated ability to influence others and foster team collaboration
  • Strong interpersonal, communication, and leadership skills!
Responsibilities
  • Reviewing US promotional, non-promotional, and scientific material, attending review meetings and providing regulatory guidance to the cross-functional team responsible for ensuring adherence to compliance standards and FDA regulations pertaining to prescription drug advertising, promotion, and communication as applicable
  • Serving as primary contact for communications with the Office of Prescription Drug Promotion (OPDP) and/or Advertising and Promotional Labeling Branch (APLB) for assigned products
  • Developing processes and procedures relevant to the creation, review and approval of advertising and promotional materials: Developing best practices, working instructions and/or SOPs to establish standards and consistency across company brands
  • As needed, providing training support within Alexion on requirements for prescription drug promotion including, but not limited to, sales training and compliance training in preparation for scientific congresses and conferences
  • Advising product development teams on advertising and promotion issues to facilitate the strategic development of new products
  • Maintaining regulatory expertise in product promotion and compliance by keeping current with issued FDA enforcement actions and through attendance of relevant conferences and/or seminars. Communicate new regulatory standards pertaining to prescription drug promotion to brand teams and management, as appropriate
  • Participating in and supporting ongoing key initiatives including the development, implementation, and continued improvement of promotional review process
  • Supporting and mentoring ad/promo colleagues
Desired Qualifications
  • JD, PharmD or master’s degree preferred

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 27, 2026 Q2 core EPS beat $2.63 versus $2.48, supporting guidance.
  • August 10, 2026 CSPC joint venture expands biologics manufacturing capacity for global supply.
  • India’s Q1 FY27 revenue rose 30%, with new approvals in CLL, MCL, and HER2+ breast cancer.

What critics are saying

  • August 3, 2026 BMS merger talks triggered a 9% stock drop, signaling investor distrust.
  • Ultomiris missed its main Phase III goal in July 2026, damaging rare-disease growth.
  • A U.S.-China decoupling would strand AstraZeneca’s $15 billion China expansion and supply network.

What makes AstraZeneca unique

  • Oncology and rare-disease breadth still anchors AstraZeneca’s premium pipeline and payer leverage.
  • Pascal Soriot’s capital discipline plus global partnerships speed launches across China, India, and Europe.
  • 2026 companion-diagnostic deals with SOPHiA Genetics deepen precision-oncology moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

5%
Mart Infomedia
Aug 13th, 2026
AstraZeneca Pharma India reports 30% revenue growth in Q1 FY27.

AstraZeneca Pharma India reports 30% revenue growth in Q1 FY27. AstraZeneca Pharma India Limited reported a strong start to FY2026-27, with total revenue from operations rising 30% year-on-year to ₹6,828 million in the first quarter ended June 30, 2026. The company said growth was supported by continued demand across its key therapy areas, including Oncology, Biopharmaceuticals covering cardiovascular, renal and respiratory diseases, and Rare Disease. The quarter also saw regulatory approvals for key medicines, new healthcare partnerships and initiatives aimed at improving diagnosis and access to treatment. Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India, said the company's first-quarter performance builds on its track record of double-digit growth over the past five years. She added that the company remains focused on investing in opportunities that can support long-term growth and value creation. Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said the company's performance reflects the strength of its portfolio and its focus on reaching more patients in India with innovative medicines. During the quarter, AstraZeneca received regulatory approval for acalabrutinib in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. The company also received approval for acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant. Another major regulatory milestone was the approval of trastuzumab deruxtecan in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. AstraZeneca also expanded its healthcare initiatives during the quarter. The company signed an MoU with the Government of Telangana to introduce AI-based lung cancer screening across 20 public healthcare facilities in urban and rural areas. The programme will use Qure.ai's AI-powered chest X-ray technology to help identify high-risk pulmonary nodules and other lung conditions, while also training healthcare professionals. The company launched K+ Connect, a nationwide initiative focused on improving the identification and management of hyperkalaemia among patients with heart failure and chronic kidney disease. In cardiovascular care, AstraZeneca launched India Coronary Conquest 2026 with STEMI India. The clinician-led programme is designed to support advanced cardiovascular care through case-based learning and professional collaboration among interventional cardiologists. AstraZeneca Pharma India also received recognition at the OPPI India Awards 2026 for its work in Rare Disease and its Hyperkalaemia and Kidney Care initiative. It also received a Gold Award at the ETHRWorld Employee Experience Awards 2026. AstraZeneca Pharma India is the listed operating company of AstraZeneca in India. It focuses on prescription medicines across Oncology, Biopharmaceuticals and Rare Disease and has more than 600 employees across the country.

Alpha Data Analytics PSA
Aug 13th, 2026
AstraZeneca ends Bristol Myers Squibb deal.

AstraZeneca ends Bristol Myers Squibb deal. Wed, August 12, 2026 at 6:22 PM GMT-7 · Consumer · Compiled by Adalytica Engine v1.12 AstraZeneca has terminated its deal with Bristol Myers Squibb, ending a collaboration that underscored how quickly pharma alliances can be reshaped by rising U.S. investment and a renewed race for oncology assets. The cancellation, disclosed in an Aug. 3 filing, matters because partnerships in cancer drug development are not just research arrangements: they can determine how fast a therapy reaches patients, how costs are shared and how much future revenue each company can capture. In a sector where pricing power and pipeline quality drive valuation, the unwinding of a major tie-up forces investors to reassess both companies' strategic flexibility and the economics of their oncology portfolios. Sentiment Indicatorsi Proprietary · adalytica.com · August 13, 2026 Healthcare Severely Stressed AstraZeneca's shares were trading at 158.5 on Aug. 12, down from 193.12 on July 7, while Bristol Myers closed at 63.70 after recovering from a June trough of 54.95. The moves point to a market that is still sorting through the implications of the breakup and the broader re-rating of large drugmakers exposed to oncology and U.S. expansion. For AstraZeneca, the decision fits a larger pattern of pharmaceutical groups concentrating capital in the U.S., where demand, regulatory scale and innovation density remain unmatched. The company has been leaning on oncology as its main growth engine, and a cleaner strategic structure may give it more control over development and commercialization decisions. But it also raises the risk that the company must shoulder more of the cost and execution burden itself. For Bristol Myers, the end of the deal removes a potential source of pipeline support at a time when investors are already focused on whether the company can sustain growth as older drugs mature. The stock has been more resilient than AstraZeneca's over the latest stretch, helped by a stronger technical profile and a sharp rebound from June lows, but the loss of a collaboration with one of the sector's strongest oncology franchises may weigh on long-term sentiment. The broader backdrop is still favorable for companies with deep cancer pipelines. U.S. spending on pharma investment is rising, Chinese biotech competition is intensifying and regulators are tightening quality expectations, pushing global drugmakers to seek scale, speed and more defensible assets. In that environment, cancelled alliances can be read two ways: as a sign that companies are becoming more disciplined about capital allocation, or as evidence that the industry's partnership model is becoming less stable as the fight for returns gets tougher. For investors, the key question is whether AstraZeneca's move strengthens its control over future upside or simply shifts more risk onto its balance sheet. The answer will depend on whether it can turn its oncology pipeline into durable revenue without the support of a major partner, and whether Bristol Myers can replace lost strategic optionality with its own dealmaking or execution gains. | Entity | Gains | Losses | | AstraZeneca | | Strategic control | | Shared development cost | | Bristol Myers Squibb | | Capital flexibility | | Pipeline optionality | | Oncology rivals | | Dealmaking leverage | | Partnership stability | | Investors | | Clearer capital plans | | Near-term uncertainty | Long AstraZeneca / Short Bristol Myers Squibb AZN keeps more oncology upside Entry 158.50 Target 170.00 Stop 151.00 R:R 1: 1.53 Trade Idea Turn this analysis into a trade. Unlock the complete setup.

Yahoo Finance
Aug 11th, 2026
Hedge funds boost AstraZeneca stake to $5.5B despite pipeline setbacks

AstraZeneca topped second-quarter profit expectations with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter brought fresh pipeline setbacks. Its rare disease drug Ultomiris missed its main goal in a late-stage trial, the latest in a string of disappointments that also includes an earlier heart drug trial failure and a breast cancer drug application that US regulators rejected. Oncology revenue rose 15%, with cancer drugs Tagrisso and Imfinzi leading growth. AstraZeneca won EU approval for its breast cancer drug Etcamah, though a US regulatory panel rejected it in May. Hedge fund holdings increased to 56 funds in Q1 2026, up from 52 the previous quarter.

Associated Press
Aug 10th, 2026
Canada approves Fasenra for hypereosinophilic syndrome, cutting flare risk by 65%

Health Canada has approved Fasenra (benralizumab) as an add-on treatment for patients aged 12 and older with hypereosinophilic syndrome (HES), a rare disorder characterised by elevated eosinophil levels that can cause organ damage. The approval follows the NATRON Phase III trial, which showed benralizumab reduced the risk of disease flares by 65% compared to placebo. In the study, 19.4% of patients receiving benralizumab experienced disease worsening versus 42.4% in the placebo group. HES affects an estimated 2,000 to 2,500 people in Canada. The condition involves persistently high levels of eosinophils in the blood, potentially leading to progressive organ damage and proving fatal if untreated. Fasenra is administered subcutaneously every four weeks. The drug is also approved in Canada for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Patient Daily
Aug 10th, 2026
AstraZeneca and CSPC to build biologics manufacturing plant in China.

AstraZeneca and CSPC to build biologics manufacturing plant in China. Lori Ellis Head of Insights | Biospace Patient Daily | Aug 10, 2026 AstraZeneca and CSPC Pharmaceutical announced on Aug. 10 a joint venture to construct a biologics manufacturing plant in Shijiazhuang, China. The collaboration is part of AstraZeneca's ongoing investment strategy in the country, which includes a commitment made in January to spend $15 billion by the end of the decade. Under the agreement, CSPC will hold a 51% equity stake while AstraZeneca will hold 49%. Both companies will contribute capital for the construction of the site located in Shijiazhuang, about 165 miles southwest of Beijing and home to CSPC's headquarters. The partners said they will jointly manage both construction and daily operations at the facility. AstraZeneca plans to leverage its global quality system and supply management experience for this project. CSPC highlighted its expertise in building "highly automated, intelligent and lean manufacturing facilities." Initially, production at the new site will focus on mutually agreed but undisclosed biologic drug substances intended for global markets. As business develops and demand grows, more products may be added to the facility's scope. According to CSPC, working with AstraZeneca supports creating high-quality manufacturing capabilities that meet international market demands. The partnership is expected to enhance CSPC's ability to serve global markets and support future overseas product launches. The joint venture expands an existing relationship between AstraZeneca and CSPC that has included several deals since 2024: $100 million upfront for rights to a preclinical lipid-lowering drug candidate; $110 million for an artificial intelligence drug development pact; $1.2 billion upfront for a GLP-1/GIP prospect; and $30 million for kidney disease collaboration. Beyond research partnerships, AstraZeneca has also invested in other Chinese facilities - including alliances with BioKangtai for vaccine production in Beijing, expansion projects such as an additional $136 million investment into Qingdao inhaled medicines plant, as well as establishing cell therapy capabilities with a new center under construction in Shanghai.

INACTIVE